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Abstract Antiplatelet therapy with clopidogrel has been
shown to reduce major adverse cardiac events in acute
coronary syndromes and after percutaneous interventions.
This effect is not only due to its anti-platelet effect but
also possibly due to an anti-inflammatory effect. The
effect of clopidogrel cessation after one year of therapy
on markers of inflammation has been investigated in
diabetics and showed an increase in platelet aggregation
as well as hsCRP and surface P-selectin levels. This was
an exploratory multicenter prospective open-label single
arm study of 98 non-diabetic patients who had received
one or more drug eluting stents and were coming to the
end of their 12 months course of clopidogrel therapy.
The effect of clopidogrel cessation on expression of
biomarkers: sCD40L, soluble P-selectin and hsCRP was
measured right before clopidogrel cessation (day 0), and
subsequently at 1, 2, 3 and 4 weeks after drug with-
drawal. A median increase in sCD40L expression from
224 to 324.5 pg/ml was observed between baseline and
4 weeks after clopidogrel cessation, which corresponded
to a 39% mean percent change based on an ANCOVA
model (P \ 0.001). Over the 4 weeks observation period
the change in sCD40L expression correlated weakly
with soluble P-selectin levels (at 4 weeks Spearman’s
correlation coefficient = 0.32; P = 0.0024). Increase in
P-selectin expression from baseline was statistically sig-
nificant at week 1 and 2. Conversely, hsCRP level
decreased by 21% at 1 week (P = 0.008) and was still
reduced by 18% by 4 weeks (P = 0.062). The change in
sCD40L expression appeared to vary with the type of
drug eluting stent. Patients treated with drug eluting
stents at 1 year after implantation display significant
increase in sCD40L and decrease in hsCRP after clopi-
dogrel cessation. Further studies should elucidate if this
increase in sCD40L levels reflects solely the removal of
the inhibitory effects of clopidogrel on platelet activity
or rather an increase in pro-inflammatory state. The latter
hypothesis may be less likely given decrease in hsCRP
levels. Randomized studies are urgently needed to
establish potential link of clopidogrel discontinuation and
vascular outcomes.
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Introduction
Addition of clopidogrel to aspirin results in reduction in
platelet reactivity [1]. This effect is particularly important
in patients that have been treated with percutaneous coro-
nary angioplasty and stenting [2]. Those who are non-
responders to clopidogrel may be at higher risk of adverse
events. Similarly, patients who interrupt their clopidogrel
therapy may be at risk of major adverse cardiovascular
event, among them stent thrombosis. Late stent thrombosis
has been shown to occur after drug eluting stent implan-
tation at a rate of 0.6% per year for up to 4 years [3]. While
the pathogenesis of stent thrombosis is likely multifacto-
rial, from stent malapposition (initial and acquired), geo-
graphic miss [4], through polymer-induced inflammation
and incomplete tissue coverage [5], it has also been sug-
gested that discontinuation of dual anti-platelet therapy
plays a role in a large proportion of cases [6, 7]. Increased
pro-coagulability after withdrawal of platelet inhibition is
likely a major factor, as incomplete platelet inhibition has
emerged as a significant risk factor for major adverse
cardiac events [8–11]. What has also emerged as a possible
mechanism is a potential increase in inflammation after
clopidogrel cessation. The role of clopidogrel, as well as
GP IIb/IIIa inhibitors, in modulating inflammation has been
documented in multiple studies in the context of acute
coronary syndrome and percutaneous coronary intervention
[12–17]. The effect of clopidogrel cessation on inflamma-
tory marker expression has not been investigated to date,
other than in a small cohort of 54 diabetic patients [8]. In
this study, platelet aggregation as well as hsCRP levels and
surface platelet P-selectin levels increased significantly at
4 weeks after cessation of clopidogrel. It is not known
whether cessation of treatment in non-diabetic patients also
leads to pro-inflammatory marker upregulation and, if so,
whether this could cause an increase in late stent throm-
bosis in a proportion of patients. In this exploratory study,
we set out to describe the changes in the levels inflam-
matory markers sCD40L, P-selectin and hsCRP within
4 weeks of clopidogrel withdrawal in a 100 non-diabetic
patients treated with stable doses of aspirin and statin.
Methods
Study design
The Discontinuation Effect of Clopidogrel After Drug
Eluting Stent (DECADES) trial was an exploratory, mul-
ticenter, open-label, single-arm study to determine the
effects of withdrawing clopidogrel therapy 12 months after
implantation of DES on markers of inflammation and
platelet activation in a non-diabetic population. The trial
took place between 31 October 2007 and 30 June 2008 and
was conducted at 6 sites in 4 European countries. The trial
was approved by the institutional review board/indepen-
dent ethics committee at every study centre. Written
informed consent for trial participation was obtained from
each patient. The trial was conducted in line with the
guidelines of the current amendment to the Declaration of
Helsinki, in accordance with the International Conference
on Harmonization of Good Clinical Practice and applicable
regulatory requirements.
Study population
Patients older than 18, who had received C1 DES of any type,
were receiving statin and low-dose aspirin therapy, and were
coming to the end of 12 months of therapy with clopidogrel
75 mg/day, were eligible to participate in the trial. Current
medication doses (including aspirin and statins) must have
been stable for 3 months. Patients were excluded from the
study if they had a clinical history of diabetes mellitus, had
uncontrolled hypertension (systolic blood pressure [
180 mmHg or diastolic BP [ 100 mmHg), were intolerant
of (or had contraindications to) aspirin or statins. The fol-
lowing patients were also excluded: those who had used
within the previous 3 months or were currently using oral
anticoagulants, dipyridamole or oral glucocorticoids; or
were taking another investigational study medication or had
taken an investigational study medication within the previ-
ous 30 days of the enrolment visit. Use of antiplatelet agents,
other than stable doses of low-dose aspirin, was prohibited
during the study.
Study protocol
After obtaining written informed consent, eligible patients
were enrolled in the study. At this time, therapy with clopi-
dogrel 75 mg/day was stopped, and stable dosages of statins
and low-dose aspirin continued. The aim of the study was to
evaluate the discontinuation effect of clopidogrel on bio-
markers by taking blood samples prior to or on the day of
Day 0 – 12 months visit 
after index PCI and  
baseline biomarker
Day 0 - Decision 
to  stop 
measurement
clopidogrel
Biomarker measurements 
after clopidogrel cessation:
Week 1
Week 2
Week 3
Week 4
Fig. 1 Study flow chart
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discontinuation of clopidogrel (baseline), and then at follow-
up visits at the end of weeks 1, 2, 3 and 4 (Fig. 1).
Safety was evaluated during the entire study period by
reporting any adverse events and serious adverse events. At
each follow-up visit patients were asked if they had
experienced any symptoms since clopidogrel withdrawal.
Biomarker assessments
Blood samples were obtained by direct venipuncture by an
experienced phlebotomist. The primary endpoint was the
mean change from baseline to week 4 in levels of sCD40L.
Secondary endpoints included changes from baseline in
plasma soluble P-selectin and hsCRP levels. All blood
samples were frozen and sent for analysis to a central
laboratory (Quintiles Limited, Livingston, UK). sCD40L,
soluble P-selectin and hsCRP levels were analysed.
Inflammation markers
The blood samples collected for immunoassays were cen-
trifuged at 1400 g for 10 min. Measurements of hsCRP,
CD40L and P-selectin were performed in duplicate by
enzyme-linked immunosorbent assay using commercially
available kits from R&D Systems (Minneapolis, MN) for
sCD40L and P-selectin and DPC Immulite for hsCRP
(Block Scientific, Holbrok, NJ).
Statistical methods
This was an exploratory study and therefore data on the
effect of withdrawing clopidogrel on sCD40L were not
available for this study population. The sample size was
not based on power considerations. Analyses were per-
formed in the clopidogrel cessation population. All patients
signed informed consent. The primary and secondary
endpoint variables were evaluated using an ANCOVA
model with baseline as covariate and investigative site as
the main effect. As all three biomarkers showed a log-
normal distribution at week 4, all ANCOVA analyses were
performed on log-transformed values (using the natural
logarithm transformation). The least-square mean was
computed using a weighting scheme based on the actual
sample sizes at each site. Data in the pre-specified analysis
are presented as mean change from baseline, with 95%
confidence intervals (CI). For all changes from baseline
analyses, only subjects with at least a baseline and one
post-clopidogrel withdrawal measurement were included.
No imputation technique was used to attempt to account for
missing data. Demographic and baseline characteristics, as
well as safety data, were summarized using descriptive
statistics, medians and interquartile ranges. Analyses were
performed using the SAS 8.2 statistical package.
As post-hoc analysis, correlation between P-selectin
levels and sCD40L was performed. In addition, the effect
of the type of DES on the change from baseline in levels of
sCD40L was assessed using an ANCOVA model with
baseline as covariate and type of DES as the main effect.
Results
Study population
A total of 103 patients were enrolled in the study and 98
patients completed the protocol. Two patients failed to have
baseline biomarker measurements. Two patients withdrew
their consent and one patient no longer met the criteria for
enrolment after baseline evaluation. Baseline characteristics
are summarized in Table 1A. They were predominantly
male with high proportion of patients having risk factors of
hypertension, hypercholesterolemia and a prior history of
myocardial infarction (63%) and none of the patients were
diabetic by trial design. Mean total duration of clopidogrel
use was 386 ± 62 days. All patients were also on stable
aspirin and statin regimens (Table 1B). The type of stent
implanted in the last procedure is listed in Table 2.
Adverse clinical events
There were no deaths, myocardial infarctions or stent
thrombosis in this patient cohort after clopidogrel cessa-
tion. Two patients represented with symptoms, one with
non-cardiac chest pain and another with angina symptoms,
which did not require catheterization.
Biomarker assessments
Changes in inflammatory markers such as sCD40L, soluble
P-selectin and hsCRP over 4 weeks after withdrawal of
clopidogrel are shown in Table 3 (medians and interquar-
tile ranges) and as mean percentage changes from baseline
levels obtained at 12 months after clopidogrel administra-
tion. CD40L levels increased from a median of 224 to
324.5 pg/ml by week four after clopidogrel cessation
(Table 3A).
P-selectin levels, on the other hand, appeared to increase
slightly two weeks after clopidogrel cessation (from 44 to
50 ng/ml; P \ 0.001) and then decreased to the baseline
levels (45 ng/ml; P = 0.488) after 4 weeks (Table 3B).
Changes in soluble P-selectin levels correlated only weakly
with changes in sCD40L levels (correlation coefficient
reached 0.32 at 4 weeks with P = 0.024; Fig. 2).
hsCRP levels decreased by 21% at 1 week (P = 0.008)
and was still reduced by 18% by 4 weeks (P = 0.062)
(Table 3C).
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sCD40L and stent type
Increase in CD40L varied with drug eluting stent used.
Patients who were treated with zotarolimus stents appeared
to have the greatest upregulation of sCD40L after clopi-
dogrel discontinuation compared to the patients treated
with paclitaxel, sirolimus eluting stents or bare metal stents
(Fig. 3). The degree of sCD40L upregulation was depen-
dent on baseline levels. There was no difference in total
stent length between stent types implanted to confound the
results.
Discussion
To our knowledge this is the first study to evaluate the
effect of clopidogrel cessation at 1 year after initial stent-
ing with drug eluting stents on inflammatory markers and
markers of platelet activation in non-diabetic patients. This
study was exploratory in nature, but nevertheless demon-
strated a significant increase in CD40L expression after
clopidogrel cessation indicative of possible enhanced
platelet activation. Although not statistically significant at
4 weeks, P-selectin level increase seemed to parallel the
CD40L changes, at least for the first 2 weeks, and corre-
lated only weakly. P-selectin levels returned to baseline by
4 weeks suggesting that the stimulus causing this transient
increase has disappeared. P-selectin is expressed upon
platelet activation and binds the P-selectin glycoprotein
ligand-1 on leukocytes [18]. P-selectin expression ulti-
mately results in tissue factor expression by the monocytes
and other inflammatory cytokines [12, 19]. More general
marker of inflammation hsCRP decreased by 21% at
1 week. This opposite effect suggests that the increase in
sCD40L levels reflects solely the removal of the inhibitory
effects of clopidogrel on platelet activity rather than an
increase in pro-inflammatory state. The interpretation of
this result is greatly limited by lack of measure of platelet
inhibition or overall thrombogenicity assay (such as
thromboelastography) [20–22].
While considerable data are now available on inflam-
matory markers and their modification with anti-platelet
therapy in the context of acute coronary syndromes and
percutaneous intervention [23, 24] it is not clear what
impact cessation of an anti-platelet agent in a stable patient
1 year post-procedure has on inflammation and pro-
coagulability. Even more difficult to interpret are con-
founding effects of drug eluting stent type. There may be a
significant interaction between endothelial dysfunction due
to local inflammation from the drug eluting stent polymer
and platelet activation. Based on the animal data from
Nakazawa et al. [25], the zotarolimus stent should have the
greatest late loss and restenosis rate but also the best
Table 1 (A) Demographic baseline patient characteristics; (B) length
of clopidogrel, aspirin and statin treatment
Variable Total (N = 98)
(A) Baseline characteristics
Age (years)
Mean 63.3
SD 8.5
Median (min, max) 63 (44, 81)
Gender, N (%)
Male/female 78/20 (79.6/20.4)
Race, N (%)
Caucasian 93 (94.9)
Asian oriental 5 (5.1)
Risk factors/comorbidities, N (%)
History of hypertension 53 (54.1)
Hypercholesterolemia 80 (81.6)
Congestive heart failure 2 (2.0)
Prior myocardial infarction 62 (63.3)
Atrial fibrillation 3 (3.1)
Stroke 4 (4.1)
Transient ischemic attack 5 (5.1)
Peripheral arterial disease 8 (8.2)
CABG 6 (6.1)
Peripheral angioplasty or bypass surgery 1 (1.0)
Current smoker 16 (16.3)
Extent of exposure to clopidogrel
and ASA and statins
Total (N = 98)
Mean; SD
(B) Time elapsed from initial clopidogrel administration
Clopidogrel use prior to withdrawal
Duration (days) 385.8; 62.4
Last dose (mg/day) 75.0; 0.0
ASA use prior to clopidogrel withdrawal
Duration (days) 763.5; 1041
Last dose (mg/day) 101.2; 27.2
Statin use prior to clopidogrel withdrawal
Duration (days) 887.3; 1394
Last dose (mg/day) 43.1; 20.5
Table 2 Type of stent implanted at index procedure
Type of DES Total (N = 98)
Implanted in most recent year, N (%)
Paclitaxel eluting stent 45 (45.9)
Sirolimus eluting stent 33 (33.7)
Zotarolimus eluting stent 18 (18.4)
Everolimus eluting stent 2 (2.0)
Other type of stent 6 (6.1)
No stent implanted in most recent year 4 (4.1)
Type of stent implanted missing 2 (2.0)
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endothelialization and the least local inflammation com-
pared to sirolimus and paclitaxel stents. These results in
animal models were ascribed to better biocompatibility of
phosphotylcholine polymer used in zotarolimus-eluting
stents than polyethelyne co-vinyl acetate and poly-n-butyl
methacrylate (sirolimus eluting stents) and polystyrene-b-
isobutyle-b-styrene (paclitaxel eluting stents). The latter
two polymers have been shown to cause inflammation,
local upregulation of tissue factor and macrophage acti-
vation [26]. We observed, however, the greatest sCD40L
upregulation after clopidogrel discontinuation in patients
treated with zotarolimus-eluting stents compared to siroli-
mus and paclitaxel drug eluting stents. This observation
needs to be explored further in future studies and may
Table 3 Change in the levels of (A) sCD40L, (B) P-selectin and (C) hsCRP over 4 weeks presented as medians and interquartile ranges as well
as mean percentage change
Baseline Week 1 Week 2 Week 3 Week 4
(A) sCD40L levels over 4 weeks after clopidogrel cessation
CD40L
Median 224 298 285.5 292 324.5
Max 1450 2483 2559 2871 2474
Min 10 36 23 42 18
Q3 364.5 478 569.5 509 541
Q1 129.5 161 160.75 155 199.5
Upper limit of normal 0 pg/ml
Lower limit of normal 5000 pg/nl
Average 310.2 434.9 469.1 412.9 446.1
Std 282.3 453.8 483.7 431.3 409.5
Mean percent change from baseline ? SE 35% ? 10% 39% ? 11% 33% ? 10% 39% ? 11%
P \ 0.001 P \ 0.001 P \ 0.001 P \ 0.001
(B) P-selectin levels over 4 weeks after clopidogrel cessation
P-selectin
Median 44 49 50 45.5 45
Max 104 114 138 147 150
Min 20 22 9 17 23
Q3 58 60.25 60.25 59 55.25
Q1 37 40 39 35 35
Upper limit of normal 51 ng/ml
Lower limit of normal 113 ng/ml
Mean 47.2 51.3 51.7 49.2 48.1
Std 16.2 17.2 18.7 20.1 20.3
Mean percent change from baseline ? SE 9% ? 2% 11% ? 2% 4% ? 3% 2% ? 3%
P \ 0.001 P \ 0.001 P = 0.173 P = 0.488
(C) Levels of CRP over 4 weeks after clopidogrel cessation
hsCRP (mg/L)
Median 1.59 1.25 1.1 1.11 1.22
Min 0.1 0.1 0.2 0.2 0.1
Max 57.9 27.7 15.6 62.9 19.5
Q3 3.70 2.61 3.46 3.29 2.83
Q1 0.74 0.72 0.66 0.62 0.61
Average 3.92 2.39 2.33 2.87 2.76
Std 7.73 3.60 2.63 6.70 3.96
Lower limit of normal 0 mg/L
Upper limit of normal 11 mg/L
Mean percent change from baseline ? SE -21% ? 7% -23% ? 7% -19.% ? 8% -18% ? 8%
P = 0.008 P = 0.004 P = 0.038 P = 0.062
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reflect a complex interaction between systemic pro-
inflammatory state, platelet activation and local peri-stent
polymer-induced inflammation.
Our results in this cohort of patients with stable coronary
disease are in agreement with Azar et al. [27], who found
only a modest decrease in sCD40L after starting clopidogrel
in stable patients (17% decrease after 8 weeks of therapy).
It appears, however, that even at 12 months post-stenting
clopidogrel still has an effect on inflammatory biomarkers
and these effects are detectable in patients treated with
stable doses of aspirin and statins. The poor correlation
between sCD40L and P-selectin while somewhat perplex-
ing, seem to echo the findings from the ELAPSE study on
proinflammatory marker levels at 12 months after com-
mencement of therapy [9]. Similarly, no correlation
between more systemic hsCRP and more-platelet/athero-
sclerosis specific sCD40L/P-selectin was found in that
study.
Lastly, a source of variability and the lack of strong
correlations between different markers in our data set could
be due to different doses of statins and potencies used in
the study. Although a given patient had to be on a stable
statin dose as the inclusion criteria, using variable doses
with different down-modulation of the pro-inflammatory
state (as reflected by hsCRP) could have made the patients
on lower statin doses more likely to upregulate inflamma-
tory markers after clopidogrel withdrawal. Ideally, when a
larger study is performed all patients should be on a single
statin such as rosuvastatin with LDL and hsCRP suppres-
sion goals optimized [28].
Limitations
Our study was limited by lack of biomarker level mea-
surements before starting clopidogrel treatment as well as
lack of concomitant data on platelet inhibition levels. The
sample size was small and the study was exploratory in
nature, and therefore not powered to detect clinical
outcomes.
Conclusions
Patients treated with drug eluting stents at 1 year after
implantation display significant increase in sCD40L and
decrease in hsCRP after clopidogrel cessation. Further
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studies should elucidate if this increase in sCD40L levels
reflects solely the removal of the inhibitory effects of
clopidogrel on platelet activity or rather an increase in pro-
inflammatory state. The latter hypothesis may be less likely
given decrease in hsCRP levels. Zotarolimus stent
implantation appears to be associated with the highest
sCD40L upregulation after stopping clopidogrel but the
clinical significance of this observation is uncertain.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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